×
-0.0373514431239389 -0.0373514431239389 -0.0373514431239389 -0.00624221844934931 -0.0152801358234295 -0.0237691001697794 -0.0418788907753255 -0.0192416525183927
Stockreport

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

DECIPHERA PHARMACEUTICALS (DCPH)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF -Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO-  -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two Pivotal Trials of DCC-2618 in 4th and 2nd Line GIST in 2018- WALTHAM, Mass., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the third quarter ended September 30, 2017, and provided an update on recent clinical and corporate developments. “In recent months, we have reported progress across key areas of our pipeline and development strategy,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera. “The data emerging from our lead program, DCC-2618, support the clinical benefit of this best-in-class pan-KIT and PDGFRa inhibitor. These encouraging results reinforce our confidence in the potent [Read more]

IMPACT SNAPSHOT EVENT TIME: DCPH
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS